Quince Therapeutics Inc (QNCX)

$0.76

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $0.75
    $0.77
    $0.76
    downward going graph

    1.91%

    Downside

    Day's Volatility :3.45%

    Upside

    1.57%

    downward going graph
  • $0.63
    $1.43
    $0.76
    downward going graph

    16.7%

    Downside

    52 Weeks Volatility :55.73%

    Upside

    46.85%

    downward going graph

Returns

PeriodQuince Therapeutics IncIndex (Russel 2000)
3 Months
-28.28%
0.0%
6 Months
-42.84%
0.0%
1 Year
-33.9%
0.0%
3 Years
-98.72%
-19.9%

Highlights

Market Capitalization
32.6M
Book Value
$1.72
Earnings Per Share (EPS)
-0.76
Wall Street Target Price
3.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-12.99%
Return On Equity TTM
-36.84%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-25.9M
Diluted Eps TTM
-0.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Quince Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 294.74%

Current $0.76
Target $3.00

Technicals Summary

Sell

Neutral

Buy

Quince Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Quince Therapeutics Inc
Quince Therapeutics Inc
7.83%
-42.84%
-33.9%
-98.72%
-98.15%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Quince Therapeutics Inc
Quince Therapeutics Inc
NA
NA
NA
0.0
-0.37
-0.13
NA
1.72
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Quince Therapeutics Inc
Quince Therapeutics Inc
Sell
$32.6M
-98.15%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on Quince Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 98.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.7% return, outperforming this stock by 292.5%

Institutional Holdings

  • TANG CAPITAL MANAGEMENT LLC

    6.82%
  • Vanguard Group Inc

    2.62%
  • EPIQ Capital Group, LLC

    1.96%
  • Renaissance Technologies Corp

    1.20%
  • BlackRock Inc

    0.77%
  • Geode Capital Management, LLC

    0.62%

Company Information

cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.

Organization
Quince Therapeutics Inc
Employees
32
CEO
Dr. Dirk Thye M.D.
Industry
Healthcare

FAQs